Pancreatic Cancer Research

ResearcherInha UniversityNo recent work listed

Zhenghuan Fang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-6684-3711; OpenAlex author ID A5017293908. Sources: OpenAlex.

Their work

Papers
10 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
15
Papers, trials and grants by year

2014: 2 papers · 2015: none · 2016: 1 paper · 2017: 1 paper · 2018: 4 papers · 2019: none · 2020: none · 2021: 1 paper · 2022: 1 paper

Papers 10

  1. Combination Therapy of the Active KRAS-Targeting Antibody inRas37 and a PI3K Inhibitor in Pancreatic Cancer. Co-author DOI 10.4062/biomolther.2021.145↗
  2. Intracellular KRAS-specific antibody enhances the anti-tumor efficacy of gemcitabine in pancreatic cancer by inducing endosomal escape. Co-author DOI 10.1016/j.canlet.2021.03.015↗
  3. A novel tropomyosin-related kinase A inhibitor, KK5101 to treat pancreatic cancer. Co-author DOI 10.1016/j.canlet.2018.03.041↗
  4. KRAS targeting antibody synergizes anti-cancer activity of gemcitabine against pancreatic cancer. Co-author DOI 10.1016/j.canlet.2018.09.013↗
  5. Melatonin Synergizes with Sorafenib to Suppress Pancreatic Cancer via Melatonin Receptor and PDGFR-β/STAT3 Pathway. Co-author DOI 10.1159/000491058↗
  6. Synthesis of Gemcitabine-Threonine Amide Prodrug Effective on Pancreatic Cancer Cells with Improved Pharmacokinetic Properties. First author DOI 10.3390/molecules23102608↗
  7. Radiosensitization of the PI3K inhibitor HS-173 through reduction of DNA damage repair in pancreatic cancer. Co-author DOI 10.18632/oncotarget.22850↗
  8. HS-173, a novel PI3K inhibitor suppresses EMT and metastasis in pancreatic cancer. Co-author DOI 10.18632/oncotarget.12871↗
  9. Crizotinib exhibits antitumor activity by targeting ALK signaling not c-MET in pancreatic cancer. Co-author DOI 10.18632/oncotarget.2363↗
  10. HS-104, a PI3K inhibitor, enhances the anticancer efficacy of gemcitabine in pancreatic cancer. Co-author DOI 10.3892/ijo.2014.2435↗

Closest collaborators

The 15 strongest of 15 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Hong Hua Yan · 9 shared papers, 2014–2022 · strength 0.67
  2. Kyung Hee Jung · 9 shared papers, 2014–2022 · strength 0.67
  3. Soon‐Sun Hong · 8 shared papers, 2014–2022 · strength 0.65
  4. Jung Hee Park · 7 shared papers, 2016–2022 · strength 0.58
  5. Yeo Wool Kang · 6 shared papers, 2017–2022 · strength 0.52
  6. Mi Kwon Son · 7 shared papers, 2014–2022 · strength 0.52
  7. Ji Eun Lee · 5 shared papers, 2017–2021 · strength 0.38
  8. Yong‐Sung Kim · 3 shared papers, 2018–2022 · strength 0.31
  9. Sungwoo Hong · 3 shared papers, 2014–2018 · strength 0.20
  10. Ji Eun Lee · 1 shared paper, 2022 · strength 0.14
  11. Marufa Rumman · 2 shared papers, 2016–2018 · strength 0.13
  12. Han‐Joo Maeng · 1 shared paper, 2018 · strength 0.10
  13. Soon Sun Hong · 1 shared paper, 2018 · strength 0.08
  14. Ye-Lim Ryu · 1 shared paper, 2014 · strength 0.04
  15. Soon‐Sun Hong · 1 shared paper, 2014 · strength 0.04

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.